Evidence map›Paper›PMID 26583890›Full record

ArticleDiabetes technology & therapeutics2016

Evaluation of a Nurse-Managed Insulin Infusion Protocol.

Andrea J Passarelli, Haley Gibbs, Annette M Rowden, Leigh Efird, Elizabeth Zink, Nestoras Mathioudakis

Abstract readEvaluation Study
In one paragraph

Article in Diabetes technology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Andrea J Passarelli1 Department of Clinical Pharmacy Services, Christiana Care Health System , Newark, Delaware.
Haley Gibbs2 Department of Pharmacy, Wake Forest Baptist Medical Center , Winston Salem, North Carolina.
Annette M Rowden3 Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, Maryland.
Leigh Efird4 Department of Pharmacy, New York-Presbyterian Hospital Weill Cornell Medical Center , New York, New York.
Elizabeth Zink5 Department of Neurology, The Johns Hopkins Hospital , Baltimore, Maryland.
Nestoras Mathioudakis6 Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Johns Hopkins Hospital · USAtrium Health Wake Forest Baptist · USJohns Hopkins Medicine · US

Funding

Institute for Clinical and Translational ResearchKL2TR001077 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$9.2M
NCATS NIH HHS KL2 TR001077
6 · The paper itself

Abstract

backgroundThe purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND

methodsThis was a retrospective observational cohort study including patients for whom the protocol was ordered from January 2012 to May 2013. Performance metrics were assessed in all patients and in patients with an initial BG level of ≥200 mg/dL. Protocol adherence was assessed in a random subset of 50 patients without hypoglycemia and in all hypoglycemic patients.

resultsIn patients with an initial BG level of ≥200 mg/dL, the mean time to goal was 7.1 h. The rate of decline of BG level in the first 6 h was 16.4 mg/dL/h. Mean BG level was 167 mg/dL, with 43.9% of BG values within goal and 80.3% between 80 and 199 mg/dL. The rate of hypoglycemic events was 0.14 per 100 h. The mean protocol violation rate was higher in patients with hypoglycemia compared with those without (39.8 vs. 23.5 per 100 h, P = 0.002), and 60.7% of hypoglycemic events were attributable to protocol violations. The protocol violation rate (42.8 vs. 17.6 per 100 h; P < 0.001) and the odds of hypoglycemia (odds ratio = 5.2; 95% confidence interval, 1.6, 16.5) were higher in the cardiac surgery patients compared with other patients.

conclusionsThis protocol provides adequate BG control within the clinically acceptable range of 80-199 mg/dL but not within the narrower range of 140-180 mg/dL, with a low incidence of hypoglycemia. Risk factors for hypoglycemia and barriers to protocol adherence in the cardiac surgery population should be elucidated.

Indexed as

Guideline AdherenceAgedBlood GlucoseCardiac Surgical ProceduresFemaleHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInfusions, IntravenousInsulinInsulin Infusion SystemsMaleMiddle AgedNursing AssessmentRetrospective StudiesBlood GlucoseHypoglycemic AgentsInsulin

Identifiers

PMID26583890
PMCPMC4808278
OpenAlexW2176754952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.